Proteintech Group Celebrates 20-Year Anniversary
Proteintech Group, a leading manufacturer of antibodies and related products, is celebrating the 20th anniversary of its founding. To celebrate the achievements and challenges of the past years, Proteintech will host special events throughout the year with its customers, collaborators, and employees while still looking forward to future opportunities.
“Over the years we have witnessed countless discoveries and we couldn’t be prouder of everything our customers have achieved. We want to thank all of our customer for their tireless efforts and sacrifices to advance scientific discovery,” Dr. Jason Li, CEO
Proteintech Group was founded in early 2001 by a small group of scientists including its current CEO, Dr. Jason Li. The founders set out with a vision to produce an antibody for every single protein coded in the human genome. Comprehensive coverage of all human gene products is a massive undertaking, but critical because it is difficult for researchers to predict which targets may be required to further scientific studies. With antibodies for two-thirds of the human genome, Proteintech has the largest self-manufactured target coverage of all antibody companies.
100,000 success stories to date
“While we are proud of our progress as a company over the past couple decades, we are most proud of what our technology has done in the hands of scientists. We’ve seen more than 100,000 citations of our products since our company establishment,” said Dr. Li. “We are excited about the future and how we can continue to help scientists apply the new technology we are working on to help people.”
Company expansion and cGMP facility
As Proteintech has continued to expand their own antibody, protein and ELISA kit product lines, they have welcomed other producers of high-quality tool providers for scientists. In April 2018, Proteintech acquired Humanzyme™, a Chicago-based manufacturer of human cell-expressed proteins, and shortly thereafter opened their cGMP facility in 2019. Using a proprietary HEK293 cell expression technology, HumanKine™ proteins are authentic human proteins with human glycosylation providing an optimized biological activity. Furthermore, they can be easily transferred from research grade, preclinical and process development to GMP grade for manufacturing in clinical trials and for commercial products.
In 2020, Proteintech acquired ChromoTek, a Munich-based manufacturer of camelid, single-domain antibodies, also known as nanobodies. These high-performance recombinant reagents will help Proteintech address opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
Over the last 20 years, Proteintech has grown in their global reach. With locations in the US, UK, Germany, Singapore, China and Japan, Proteintech is able to provide fast delivery around the world. Now with over 300 employees worldwide, Proteintech is setting their sights on continuing to support the future of science with quality, transparency, and customer needs in mind.
For more information on Proteintech and their products please visit ptglab.com. For the event page please visit ptglab.com/news/company-news/celebrating-our-20th-anniversary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005887/en/
Contact information
Thompson + Conard Communications
Jane Thompson
jane@thompsonconard.com
1-415-710-1675
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 09:00:00 CET | Press Release
Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founder, Nexo, noted: “The Australian Open stands at the intersection of excellence and ambition – precisely where Nexo positions itself. Our partnership reflects a shared commitment to disciplined performance and long-term thinking. We are honored to join Tennis Australia in elevating the sport while showcasing the value of int
Jerrod Chong, Yubico ’ s Chief Operating Officer, appointed as acting CEO17.12.2025 08:05:00 CET | Press Release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and the leading provider of hardware authentication security keys, today announced that Jerrod Chong, Yubico’s current Chief Operating Officer, has been appointed to serve as acting CEO. Mattias Danielsson will be stepping down from his role as CEO of Yubico. "I am very pleased that Jerrod has accepted the role of acting CEO. With his extensive experience in cybersecurity and twelve years in senior leadership at Yubico, I am confident that he will lead Yubico on a continued path of growth and he will ensure Yubico maintains and strengthens its leading position. On behalf of the board, I also want to extend our sincere thanks to Mattias Danielsson for his hard work and significant contributions to Yubico’s development as a respected leader and colleague over sixteen years. We deeply appreciate his commitment to Yubico over the years," says Patrik Tigerschiöld, Chairman of the Board. "Yubico is entering an excitin
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 08:00:00 CET | Press Release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 08:00:00 CET | Press Release
Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks the company's entry into the Zero Trust Workforce Access market and lays the foundation for its identity security division, Specops, to offer a unified appr
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom